Last reviewed · How we verify
Clostridium Botulinum Toxin Type A
Clostridium botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Clostridium botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Clostridium Botulinum Toxin Type A |
|---|---|
| Also known as | NABOTA, BOTOX |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | Neurotoxin; botulinum toxin |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Aesthetics; Pain Management |
| Phase | FDA-approved |
Mechanism of action
The toxin is a zinc-dependent endopeptidase that cleaves SNAP-25 (synaptosome-associated protein of 25 kDa), preventing the fusion of acetylcholine-containing vesicles with the presynaptic membrane. This results in temporary paralysis of muscles at the injection site, lasting 3-4 months before neuromuscular function gradually recovers through sprouting of new nerve terminals.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Chronic migraine
- Spasticity
- Hyperhidrosis
- Cosmetic wrinkle reduction
Common side effects
- Headache
- Neck pain
- Injection site pain
- Muscle weakness
- Dysphagia
- Dry mouth
- Flu-like symptoms
Key clinical trials
- DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia (PHASE1, PHASE2)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
- Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: